Mersana Therapeutics (NASDAQ: MRSN) reported Q1 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $9.24 million versus the consensus estimate of $7.93 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.